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ABSTRACT: The members of the Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) have shown great interest in developing a common GRAPPA 
database. To address this interest, GRAPPA included a symposium at its 2017 annual meeting 
to examine the concepts of registries and databases. At this symposium, examples of existing 
databases were reviewed and their challenges and achievements were discussed. 
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Psoriatic arthritis (PsA) is a complex condition characterized by a variety of clinical 
manifestations and disease courses. As with other similar conditions, the best way to 
understand the course of disease and patient prognosis is through observational cohort studies. 
These studies depend on the prospective collection of data on a large number of patients 
followed according to standard protocols.(1) At the GRAPPA 2017 annual meeting in 
Amsterdam, The Netherlands, examples of existing databases were reviewed and their 
challenges and achievements were discussed.  
Dr. Dafna Gladman (Toronto, Ontario, Canada) discussed the differences between 
registries and cohorts. She stated that there are several types of registries, including 
administrative registries, registries for clinical trials, registries for genetic studies, registries for 
biologics, and registries for longitudinal observational studies.  
Administrative registries are set up for administrative purposes to record patients with 
individual diagnoses and usually do not include detailed information about individual patients or 
their disease course. Some contain information on medications, hospitalizations and health care 
utilization. Moreover, the validity of the diagnosis is often unproven. Registries for clinical trials 
record patients with the disease in question and include only the minimum information 
necessary to determine whether a patient is eligible for a clinical trial. Registries for genetic 
studies include patients with a particular disease (and usually also include healthy controls) and 
include minimal disease process information, but detailed genetic analyses information. 
Registries for biologics usually include only the minimum information necessary to determine 
therapy response and any particularly adverse events that relate to the therapy. Registries for 
longitudinal observational studies usually include more detailed information and are generally 
considered databases as opposed to registries (Table 1). Compared to clinical trials, 
longitudinal databases include all patients, record all drugs, provide long-term observation with 
a large sample, have inclusive information, and record all possible outcomes. Thus, databases 
provide the prospective collection of data from a large number of patients and use standardized 
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protocols, including clinical, laboratory, imaging, and genetic data. These data are collected 
over a long observation period, which allows for varied presentations and courses to be 
analyzed. In addition, databases require computer tracking of all information. This allows for the 
description of disease course and long-term medication complications, the understanding of 
pathogenesis, and the study of associations between disease course and drug therapy. In 
addition, this provides insight into disease progression and allows researchers to plan for future 
trials. 
To gain the most benefit from databases and to be able to replicate or increase the 
power of specific observations, it is important that similar registries have the same information 
collected in a similar way. Thus, clinical and laboratory assessment should be confirmed to be 
similar and the consistency of variables must be assured. The actual platform need not be the 
same as long as harmonization between items is confirmed. Whatever database platform is 
used, it must allow for the easy transfer of data to a statistical system for data analysis. 
It is important to avoid selection bias and demonstrate internal and external validity.  
Methods of observation and measurement must be clearly defined, and complete follow-up 
should be attempted to avoid information bias. It is also important to consider confounding 
factors such as time and intervention, although these may be overcome by design and analysis. 
Dr. Gladman provided an example of the database from the University of Toronto 
Psoriatic Arthritis Program. The Toronto cohort currently includes 1450 patients and has been 
operating since 1978. Patients are assessed at 6-12 month intervals according to a standard 
protocol.(2) The reliability of joint assessment has been proven through a number of studies,(3, 
4) and the radiographic method has also been proven reliable.(5) In addition, patients lost-to-
follow-up and those followed regularly had similar disease characteristics at presentation.(6)  
Dr. Gladman highlighted the challenges of setting up a computer database, including 
quality assurance, data entry costs, issues with exporting data for statistical analysis, and the 
 
 
2 November 2017  Page 5 of 12 
 
large number of staff required to maintain a database. Nonetheless, the database provided 
substrate for multiple investigations.  
Current and Proposed PsA Cohorts 
Dr. Marijn Vis (Rotterdam, The Netherlands) discussed the Dutch cohort of PsA, which is 
comprised of 40 rheumatologists from 11 hospitals in the southwest of The Netherlands. The 
Dutch cohort’s mission is to improve care for patients with psoriatic arthritis through education, 
research, and standardization. To set up their database, the Dutch cohort involved 
rheumatologists and patients with unmet needs who set up a clinical and science committee. 
Members contributing to the cohort own their own data. If possible, lab results, medication, and 
other data are taken directly from the hospital data warehouse with patient questionnaires 
completed online. These data are all imported into one database. Data warehouses are used to 
store data from the hospitals’ electronic patient files, and data collection is currently semi-
automatic. To date, there are over 500 patients included in this database. In addition to the 
scientific use of data, the data will also be used, together with the automatic data import, to 
create a support tool for clinical care. The aim is to develop a decision support system to assist 
physicians in using the appropriate treatment for the right patient based on the information 
collected in the database.  
Drs. Laura C. Coates (Oxford, United Kingdom), William Tillett (Bath, United Kingdom), 
and Deepak Jadon (Cambridge, United Kingdom) presented a collaboration from the United 
Kingdom (UK) that will establish a cohort with embedded trials using a new methodology. This 
cohort will recruit patients from Oxford, Bath, and Cambridge starting in 2018. The Trials within 
Cohorts (TWiCs) or cohort multiple randomized controlled trial (cmRCT) design will be used and 
was first published in 2010. This method recruits a central cohort having “treatment as usual” 
with regular observations and then adds pragmatic trials of alternative therapies. Eligible 
patients for trials are identified in the cohort and randomized to the offer of an intervention or to 
remain as controls in the cohort. 
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This design is particularly useful for open-label efficiency comparisons of therapeutic 
interventions with “treatment as usual” as the comparator. It is ideal for chronic conditions and 
where expensive desirable treatments are being trialed. It allows robust generalizability from 
studies to routine health care, avoids attrition and disappointment bias from controls in open 
label studies as patients only receive information relevant to their care, aids recruitment to trials, 
allows routine collection of long-term outcomes, and increases efficiency with multiple trials 
within one cohort.(7)   
In collaboration, members of the group are establishing a cohort of early PsA patients 
who will all receive step-up treatment guided by a treat-to-target (T2T) approach. This will form 
the central cohort and will collect outcome data on a real-world feasible T2T model. At present, 
two interventional trials are planned: the first in mild PsA with low disease impact where patients 
will not be prescribed the usual disease-modifying therapy, and the second in moderate-severe 
PsA where patients will be offered more aggressive therapy.   
A number of TWiCs studies are currently running across Europe with the majority in the 
oncology field. The UK cohort study will be the first in rheumatology and also one of the first 
TWiCs studies testing investigational medicinal products. This has required appropriate liaison 
with regulators during protocol development. There are challenges, including ethical and GCP 
issues with consent, and also that data collection must balance the robustness necessary for 
clinical trial and feasibility for regular clinic. Many people are unfamiliar with the TWiCs concept, 
which has made it important to connect and educate university staff, charity and industry 
funders, clinical trials units, and ethics and medicines regulatory authorities. 
In Oxford, the cohort will be new and has been established specifically as a TWiCs 
study. In Cambridge, the cohort is new. In Bath, the cohort is pre-existing. Discussions between 
the three centers have aligned outcomes and time-points for data collection to allow this 
collaboration. 
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Dr. Deepak Jadon (Cambridge, United Kingdom) is harmonizing a group of 750 PsA 
cases, historically looked after by 10 consultants at the Addenbrooke’s Hospital, into a single 
cohort looked after in a dedicated PsA service that started in 2015. Using the EPIC platform, 
clinical data are collected to an electronic patient record system. In late 2017, electronic tablets 
will be used to collect patient reported outcome measures (PROM) in the clinic waiting area and 
from home. The cohort includes both inception patients and prospective, established PsA 
patients. The program includes a consultant, research fellow, resident, research nurse, and PsA 
specialist nurse. The program takes direct referrals from general practitioners, dermatologists, 
gastroenterologists, ophthalmologists, and internal referrals. All patients undergo a protocoled 
series of PROMs, examination indices, imaging, and laboratory tests. Patients have the 
opportunity for education and counselling about their condition as well as management by the 
PsA specialist nurse and doctors. They also have the opportunity to attend 6 monthly patient 
and family education evenings hosted by Dr. Jadon.  
In keeping with GRAPPA recommendations for the management of PsA,(8) 
multispecialty working has been a tenant of providing a holistic PsA service. In 2016, a monthly 
dermatology-PsA multi-disciplinary team (MDT) meeting, 2 monthly inflammatory bowel disease 
(IBD)-spondyloarthritis MDT meetings, and 2 monthly hepatology-PsA MDT meetings were 
established. These MDT meetings are attended by consultants, trainees, fellows, and specialist 
nurses. Complex patients, diagnostic conundrums, and treatment escalation are discussed, with 
a view to ensuring more harmonized care of the multiple facets of psoriatic disease. The MDTs 
have also forged screening initiatives for PsA in PsC patients and for spondyloarthritis in IBD 
patients. The challenges of setting up this PsA service have included optimizing patient flow 
between the MDT, internet technology solutions to enable direct referrals to the PsA clinic, 
funding and implementing the electronic data collection initiative using tablets, funding 
dedicated PsA staff and job planning, and convincing commissioners and funders of the clinical 
and economic virtues such a service provides to both patients and the hospital. 
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Dr. William Tillett (Bath, United Kingdom) presented a historical perspective on the Bath 
PsA cohort and the opportunities and challenges of integrating a new TWiCs cohort into an 
established cohort database. The Bath PsA cohort was set up in 1989 by Professor Neil 
McHugh to answer questions about the PsA disease pathogenesis, clinical manifestations, 
prognostic indicators, the natural course of disease, and the real world effect of treatment. The 
cohort is a secondary-care cohort primarily serving the local community (95%) with 5% of 
participants coming as tertiary referrals from farther afield in the UK. As such, the cohort broadly 
represents patients with PsA in the UK. Patients are recruited to the cohort with any disease 
duration, including both new and established diagnoses (thus, it is not purely an inception 
cohort). In addition to a baseline set of data, clinical, patient-reported, and radiographic data is 
collected at routine clinical reviews (every 3 months for patients with active disease and every 6 
months for those with more stable disease). Additional cross-sectional and longitudinal sub 
studies have been undertaken to answer specific questions over the last 28 years. Patients and 
clinicians have historically collected data on paper, and this data is then scanned into a 
database where it is monitored and validated by a database team. 
Ensuring that the cohort fulfils the most up-to-date PsA classification criteria has been an 
important consideration over time. Initially, entry to the cohort was based on physician 
diagnosis, then the application of Moll and Wright criteria, and finally retrospectively applying 
CASPAR classification criteria.(9) Several milestones have necessitated changes to the data 
collected such as the introduction of biologic therapies, the need for more clinical and mediation 
data collection and development, and changes to the Outcome Measures in Rheumatology 
(OMERACT) Core set of domains as measures in randomized controlled studies and 
longitudinal observational studies.(10, 11) 
The decision to set up a new TWiCs subcohort in Bath coincided with a recognition of 
the importance of moving to electronic data capture and integration with other clinical systems 
to widen the routinely collected research data. It became clear after discussions between 
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Oxford, Cambridge, and Bath that having a single data collection platform across sites would 
not be achievable with the different organizations’ funding priorities and existing contract 
commitments. The solution was to avoid real-time data upload and instead upload study data 
from existing systems at set time points during the study. A decision was made to harmonize 
datasets based on the OMERACT core set using the best validated and most feasible 
measures. Feasibility of data collection was a significant consideration as each site has different 
clinic structures and staff resources. A dataset that could be achieved at each site was 
negotiated. 
Prior to the open discussion about cohorts, Dr. Philip Mease (Seattle, Washington, USA) 
discussed the Corrona Registry, a consortium of investigative centers in the United States that 
began as a registry for rheumatoid arthritis and PsA but more recently added patients with 
spondyloarthritis.(12) The Corrona Registry collects detailed information on clinical disease 
manifestations, including enthesitis, dactylitis, spine and skin disease, comorbidities, and the 
treatment of these diseases. This registry, however, only captures imaging data as done in 
practice and has no biobanking component. This registry has generated a number of recent 
publications.(13-15)  
During the discussion, GRAPPA members were interested in the difficulties of setting up 
the cohorts, the financial considerations, as well as the feasibility of collecting detailed 
information on all patients.  
GRAPPA members have expressed interest in developing a GRAPPA database, a 
concept that was further discussed during the research meeting that followed the 2017 
GRAPPA annual meeting. 
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Table 1: Information collected in different registry types 
Type of Registry Information collected 
Administrative Demographic 
Clinical Trials Demographic plus some clinical information especially drugs 
Genetic Studies Proband and family information including enough details to define a 
phenotype together with genetic information 
Biologic Registries Demographic, clinical, and therapeutic information to determine response 
and adverse events 
Cohort Database As much detail as possible to follow disease progression and identify new 
features 
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